BiotechTube
Scarcell Therapeutics

Scarcell Therapeutics

Paris, France· Est.
scarcell.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Scarcell Therapeutics is a clinical-stage biotech developing an allogenic gingival fibroblast (aGF) platform for regenerative medicine, initially targeting osteoarthritis. Its lead candidate, aGF, is a single-injection therapy with demonstrated safety and efficacy in over 800 companion animals and is preparing for Phase Ib human trials in Europe in mid-2025. The company's technology leverages the immune-tolerant properties of gingival fibroblasts to enable long-lasting effects without immunosuppression, positioning it as a potential disease-modifying therapy in a large, underserved market.

OsteoarthritisDegenerative DiseasesInflammatory Diseases

Technology Platform

Allogenic Gingival Fibroblast (aGF) cell therapy platform. Utilizes immune-tolerant fibroblasts from gum tissue for regenerative medicine, enabling long-lasting effects without immunosuppression. Patented cell therapy and GMP bioprocess.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The global osteoarthritis market represents a multi-billion dollar opportunity with no approved disease-modifying therapies, creating a clear path for a regenerative product like aGF.
Success in OA could validate the aGF platform for expansion into other large chronic disease markets such as vascular and dermatological conditions.

Risk Factors

Key risks include the failure of promising animal data to translate to human safety and efficacy in upcoming clinical trials, the significant regulatory hurdles for a novel allogeneic cell therapy, and intense competition from other regenerative medicine approaches in a capital-intensive sector.

Competitive Landscape

Scarcell competes in the regenerative medicine for osteoarthritis space, which includes companies developing autologous and allogeneic mesenchymal stem cell (MSC) therapies, platelet-rich plasma (PRP), and other biologic approaches. Its differentiation lies in the specific immune-tolerant properties of gingival fibroblasts and its single-injection, off-the-shelf allogeneic model.

More companies in Cell & Gene Therapy →More companies in France →